Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 458-461, December 2009

Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma

  • Bao-sheng Li

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Tao Zhou

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Zhong-tang Wang

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Hong-sheng Li

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Hong-fu Sun

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Zhi-cheng Zhang

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Hai-qun Lin

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Yu-mei Wei

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • He-yi Gong

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Wei Huang

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Yan Yi

      Affiliations

    • Sixth Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • ,
  • Li-ying Wang

      Affiliations

    • Department of Medicine Oncology, Shandong Cancer Hospital, Shandong Province, PR China
    • Corresponding Author InformationCorresponding author. Address: Department of Medicine Oncology, Shandong Cancer Hospital, No. 440, Ji-Yan Rd., Ji-Nan, Shandong Province, PR China.

Received 24 April 2009; received in revised form 1 August 2009; accepted 11 August 2009. published online 07 September 2009.

Abstract 

Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500mg. The maximum-tolerated dose/recommended dose of Capecitabine was 1000mg. The Kaplan–Meier estimated overall l-year survival rate was 100%.

Keywords: Esophageal cancer, Selective lymph node late course accelerated hyper-fractionated radiotherapy, Chemo-radiotherapy, Capecitabine, Cisplatin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(09)00435-6

doi:10.1016/j.radonc.2009.08.002

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 458-461, December 2009

Article Tools